For example, Talimogene Laherparepvec (Oncolytic Herpes Simplex Virus-1 expressing GM-CSF) (T-VEC) [18], the first approved oncolytic virus therapy, through inducing tumor cell lysis, then releasing GM-CSF, promoting dendritic cell maturation and antigen presentation, thus activating tumor specific T cells, has shown significant efficacy in the treatment of melanoma (Optim Test showed that the target effective rate was 31.5%) [66,67]. The gene discussed is CSF2; the disease is melanoma.